<DOC>
	<DOCNO>NCT00349258</DOCNO>
	<brief_summary>To compare incidence ovarian hyperstimulation syndrome ( OHSS ) implantation rate high responder patient use Gonadotropin release GnRH ) agonist human chorionic gonadotropin ( hCG ) trigger final oocyte maturation .</brief_summary>
	<brief_title>The Use GnRH Agonist Trigger Prevention OHSS</brief_title>
	<detailed_description>OHSS iatrogenic complication control ovarian hyperstimulation , severe form , may result significant morbidity . Although , significant advance in-vitro fertilization ( IVF ) protocols year , incidence OHSS remain stable currently effective way prevent disorder . hCG commonly use substitute endogenous LH surge induce final oocyte maturation IVF . Unfortunately , hCG result prolong luteotropic effect long half-life may result potential risk OHSS high-risk patient . In contrast , induction endogenous LH surge GnRH agonist may result reduce risk OHSS . This due short half-life endogenous LH surge subsequent pituitary suppression lead early luteolysis . However , previous study suggest approach may impair implantation rate . There randomized study assess effect GnRH agonist induce oocyte maturation occurrence OHSS implantation rate high-risk patient . The aim study compare incidence OHSS implantation rate among high-risk patient use either GnRH agonist hCG trigger oocyte maturation prevention premature LH surge either GnRH antagonist protocol dual pituitary suppression protocol , respectively . High risk patient include woman polycystic ovarian syndrome ( PCOS ) PCO morphology ( PCOM ) ultrasound without clinical biochemical evidence syndrome , patient previous high response gonadotropin .</detailed_description>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>age 2039 normal early follicular phase serum FSH ( â‰¤10.0 IU/l ) patient either PCOS PCOM undergo first cycle IVF patient high response previous IVF cycle . Hypogonadotropic hypogonadism</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>OHSS</keyword>
	<keyword>PCOS</keyword>
	<keyword>Previous high response</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>IVF</keyword>
</DOC>